Cumberland Pharmaceuticals Inc.
NASDAQ:CPIXDrug Manufacturers - Specialty & Generic
-$0.06 today
- Market cap
- $98.52M
- Beta
- 0.10
- P/E (TTM)
- -11.5
- EPS (TTM)
- -$0.48
Volume 0.16M
Average 0.97M
CPIX Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Cumberland Pharmaceuticals Inc.NASDAQ: CPIX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $1.28M fell 3.1% year over year, ahead of the -16.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.8% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.
Context
- Depreciation & amortization amounted to 11.9% of revenue in FY2025, down 4.1 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -3.1% holds above the trailing-twelve-month pace of -16.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 5.29M USD
- Year-over-year change
- -12.5%
- 4-year CAGR
- +3.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.29M | -12.5% |
| FY2024 | 2024-12-31 | 6.04M | -25.4% |
| FY2023 | 2023-12-31 | 8.1M | +52.1% |
| FY2022 | 2022-12-31 | 5.33M | +15.7% |
| FY2021 | 2021-12-31 | 4.61M | — |
Depreciation & Amortization vs competitors
How CPIX compares with its peers on the latest reported figures
- CPIX's LTM Mar 2026 depreciation & amortization of $4.96M is the 2nd highest of the 4 companies compared; the peer median is $18.34K.
- Its year-over-year change of -16.3% is the 3rd highest of 4, against a peer median of -7.4%.
- Depreciation & amortization amounts to 11.8% of revenue for CPIX, versus a peer median of 14.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $7.34M | -7.4% | -8.2% | 27.6% | |
| LTM Mar 2026 | $4.96M | -16.3% | -0.3% | 11.8% | |
| LTM Mar 2026 | $18.34K | +12.3% | — | 0.6% | |
| LTM Mar 2026 | $16.56K | -74.3% | +19.7% | — | |
| Peer median (excluding CPIX) | $18.34K | -7.4% | +5.7% | 14.1% | |
Competitors are the stored peer set for CPIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 35.99M | 42.01M | 39.55M | 37.87M | 44.52M |
| Cost of Revenue | 8.81M | 9.12M | 6.07M | 6.59M | 6.67M |
| Gross Profit | 27.17M | 32.89M | 33.49M | 31.28M | 37.85M |
| Gross Margin | 75.5% | 78.3% | 84.7% | 82.6% | 85.0% |
| Research & Development | 5.68M | 6.69M | 5.83M | 4.82M | 5.57M |
| Selling, General & Admin | 24.8M | 26.84M | 29.1M | 28.15M | 31.05M |
| Operating Expenses | 34.85M | 38.6M | 43.04M | 37.71M | 40.65M |
| Depreciation & Amortization | 4.61M | 5.33M | 8.1M | 6.04M | 5.29M |
| EBITDA | (857.83K) | 332.92K | 2.49M | 182.42K | 2.96M |
| EBITDA Margin | -2.4% | 0.8% | 6.3% | 0.5% | 6.6% |
| Operating Income | (7.68M) | (5.7M) | (9.55M) | (6.43M) | (2.79M) |
| Operating Margin | -21.3% | -13.6% | -24.2% | -17.0% | -6.3% |
| Interest Income | 26.08K | 98.41K | 286.85K | 334.44K | 476.75K |
| Interest Expense | 98.03K | 586K | 667.86K | 605.51K | 495.99K |
| Other Income / Expenses | 2.12M | 123.74K | 3.27M | (33.98K) | (32.46K) |
| Income Before Tax | (5.56M) | (5.58M) | (6.28M) | (6.47M) | (2.82M) |
| Pre-Tax Margin | -15.5% | -13.3% | -15.9% | -17.1% | -6.3% |
| Income Tax Expense | 34.89K | 68.85K | 45.77K | (22.67K) | 40.26K |
| Net Income | (3.51M) | (5.57M) | (6.28M) | (6.48M) | (2.84M) |
| Net Margin | -9.7% | -13.3% | -15.9% | -17.1% | -6.4% |
| EPS (Basic) | (0.24) | (0.38) | (0.44) | (0.46) | (0.19) |
| EPS (Diluted) | (0.24) | (0.38) | (0.44) | (0.46) | (0.19) |
| Weighted Avg Shares | 14.9M | 14.56M | 14.3M | 14.06M | 14.96M |
| Weighted Avg Shares (Diluted) | 14.9M | 14.56M | 14.3M | 14.06M | 14.96M |
Cumberland Pharmaceuticals Inc.
NASDAQ:CPIX
Intrinsic Alpha fair value
Locked
Current Price
$6.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.